ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Oncolytics Biotech Inc

Oncolytics Biotech Inc (ONC)

1,66
0,07
(4,40%)
Fermé 04 Novembre 10:12PM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
1,66
Prix Achat
1,61
Prix Vente
1,70
Volume échangé
85 905
1,59 Fourchette du Jour 1,67
1,15 Plage de 52 semaines 2,46
Clôture Veille
1,59
Ouverture
1,60
Dernière Transaction
100
@
1.66
Dernière heure de transaction
Volume moyen (3 m)
107 408
Volume financier
-
VWAP
-

ONC Dernières nouvelles

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS

THE PANCREATIC CANCER ACTION NETWORK SELECTS ONCOLYTICS BIOTECH® INC. TO RECEIVE $5 MILLION THERAPEUTIC ACCELERATOR AWARD TO DEVELOP LEADING-EDGE TREATMENTS PR Newswire BOSTON and SAN DIEGO and...

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024 FN Media Group Presents USA News Group News Commentary PR Newswire VANCOUVER, BC, Jan. 10, 2022...

Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor ...

CALGARY, Alberta and SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...

Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Pr...

- Increased PD-L1 expression correlates with clinical response when pelareorep is combined with a proteasome inhibitor - - Data continue to recommend pelareorep as a standardized backbone for...

Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer

CALGARY, Alberta and SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...

Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancrea...

CALGARY, Alberta and SAN DIEGO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...

Oncolytics Biotech® Announces Attendance of Upcoming Conferences

CALGARY, Alberta and SAN DIEGO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered...

Oncolytics Biotech® Reports 2018 Third Quarter Financial Results and Provides Corporate Update

- Checkpoint combination studies support progression into registration pathway for metastatic breast cancer and potential expansion of indications - - Management to host webcast and conference...

Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregul...

- Oncolytic virus enhances immune checkpoint inhibitor response in prostate cancers - CALGARY, Alberta and SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.07-4.046242774571.731.761.56705181.66895876CS
40.3627.69230769231.32.081.292223391.73201357CS
120.322.05882352941.362.081.151074081.57894962CS
260.149.210526315791.522.081.15661521.55242434CS
52-0.65-28.13852813852.312.461.15711161.59216162CS
156-0.88-34.64566929132.544.491.06800272.27500808CS
2600.127.792207792211.547.841.061353443.0904901CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
EPRXEupraxia Pharmaceuticals Inc
$ 4,30
(30,30%)
293,08k
RAY.BStingray Group Inc
$ 7,59
(24,02%)
2,55k
NUMINuminus Wellness Inc
$ 0,03
(20,00%)
16,85k
AREAecon Group Inc
$ 27,51
(18,63%)
1,3M
RTGRTG Mining Inc
$ 0,04
(14,29%)
23,5k
VRTSVertiqal Studios Corporation
$ 0,01
(-33,33%)
8k
PPRPrairie Provident Resources Inc
$ 0,03
(-25,00%)
1,12M
FLNTFlint Corporation
$ 0,02
(-20,00%)
11,01k
AEGAegis Brands Inc
$ 0,36
(-14,29%)
26k
XMF.AM Split Corp
$ 0,40
(-12,09%)
10k
ACAir Canada
$ 21,50
(13,94%)
17,13M
VRNVeren Inc
$ 6,94
(-3,21%)
9,07M
ENBEnbridge Inc
$ 56,43
(0,34%)
8,64M
BTEBaytex Energy Corp
$ 4,08
(3,82%)
8,56M
MFCManulife Financial Corporation
$ 41,13
(1,13%)
6,67M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock